CTOs on the Move

Intact Vascular

www.intactvascular.com

 
Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System™ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Intact Vascular raised $38M on 05/14/2015
Intact Vascular raised $46M on 01/03/2017
Intact Vascular raised $20M on 04/16/2018
Intact Vascular raised $25M on 05/30/2019

Similar Companies

Feldan Therapeutics

Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the recent development of the Feldan Shuttle, this approach is starting to show its promises. Feldan`s mission is to develop regenerative medicine therapeutic applications based on Feldan`s proprietary technology.

VGXI

VGXI is a Spring, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trait Biosciences

Trait Biosciences Inc. is a leading biotechnology research organization providing proprietary technology to enable safer, lower cost, predictable, and superior quality cannabinoid products. With a world-class team of scientists and PhDs from more than 20 countries collaborating in our state-of-the-art Los Alamos laboratory, Trait Biosciences researchers are unlocking new breakthroughs in cannabinoid science. Trait Biosciences offers transformative technologies that create water-soluble cannabinoids, increase cannabinoid production, protect the plants from disease, tailor the production of cannabinoids and that can assure zero THC for hemp.

NexImmune

NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology.

Eidos Therapeutics

Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis.